A Pharmacokinetics (PK) Study to Investigate the Effect of Rifampin on PK of Vemurafenib (Zelboraf)

Exclusion Criteria

• •Prior treatment with vemurafenib or other BRAF inhibitor within 42 days of first dose of study drug
• •Requirement for immediate or urgent treatment with daily vemurafenib and for whom the intermittent schedule of vemurafenib employed during the 24-day period for this trial is not clinically acceptable
• •Allergy or hypersensitivity to components of the vemurafenib formulation
• •Experimental therapy within 4 weeks prior to first dose of study drug
• •Major surgical procedure or significant traumatic injury within 14 days prior to first dose of study drug, or anticipation of the need for major surgery during study treatment
• •Prior anti-cancer therapy within 28 days before the first dose of study drug
• •History of clinically significant cardiac or pulmonary dysfunction
• •History of symptomatic congestive heart failure of any New York Heart Association class or serious cardiac arrhythmia requiring treatment
• •History of myocardial infarction within 6 months prior to first dose of study drug
• •Current dyspnea at rest, owing to complications of advanced malignancy or any requirement for supplemental oxygen to perform activities of daily living
• •History of congenital long QT syndrome or corrected QT interval (QTc) greater than (\>) 450 milliseconds
• •Active central nervous system lesions
• •Uncontrolled or poorly controlled diabetes
• •Current severe, uncontrolled systemic disease